ECOR Quote, Financials, Valuation and Earnings

NeuroMetrix has a net margin of -38.1% compared to electroCore's net margin of -256.8%. electroCore's return on equity of -144.52% beat NeuroMetrix's return on equity of -41.7%.

electroCore has a consensus price target of $27.47, signalling upside risk potential of 81.44%. On the other hand NeuroMetrix has an analysts' consensus of -- which suggests that it could grow by 10156.41%. Given that NeuroMetrix has higher upside potential than electroCore, analysts believe NeuroMetrix is more attractive than electroCore.

electroCore has a beta of 0.574, which suggesting that the stock is 42.566% less volatile than S&P 500. In comparison NeuroMetrix has a beta of 2.182, suggesting its more volatile than the S&P 500 by 118.234%.

electroCore has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroMetrix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. electroCore pays -- of its earnings as a dividend. NeuroMetrix pays out -- of its earnings as a dividend.

electroCore quarterly revenues are $6.6M, which are larger than NeuroMetrix quarterly revenues of $587.3K. electroCore's net income of -$2.5M is lower than NeuroMetrix's net income of -$1.5M. Notably, electroCore's price-to-earnings ratio is -- while NeuroMetrix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for electroCore is 4.60x versus 1.81x for NeuroMetrix. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -38.1% compared to electroCore's net margin of -18.58%. electroCore's return on equity of -144.52% beat Retractable Technologies's return on equity of -16.83%.

electroCore has a consensus price target of $27.47, signalling upside risk potential of 81.44%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that electroCore has higher upside potential than Retractable Technologies, analysts believe electroCore is more attractive than Retractable Technologies.

electroCore has a beta of 0.574, which suggesting that the stock is 42.566% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

electroCore has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. electroCore pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

electroCore quarterly revenues are $6.6M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. electroCore's net income of -$2.5M is lower than Retractable Technologies's net income of -$1.9M. Notably, electroCore's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for electroCore is 4.60x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -38.1% compared to electroCore's net margin of -4291.67%. electroCore's return on equity of -144.52% beat Catheter Precision's return on equity of -65.84%.

electroCore has a consensus price target of $27.47, signalling upside risk potential of 81.44%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than electroCore, analysts believe Catheter Precision is more attractive than electroCore.

electroCore has a beta of 0.574, which suggesting that the stock is 42.566% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

electroCore has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. electroCore pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

electroCore quarterly revenues are $6.6M, which are larger than Catheter Precision quarterly revenues of $96K. electroCore's net income of -$2.5M is higher than Catheter Precision's net income of -$4.1M. Notably, electroCore's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for electroCore is 4.60x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -38.1% compared to electroCore's net margin of -17.98%. electroCore's return on equity of -144.52% beat Xtant Medical Holdings's return on equity of -35.98%.

electroCore has a consensus price target of $27.47, signalling upside risk potential of 81.44%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than electroCore, analysts believe Xtant Medical Holdings is more attractive than electroCore.

electroCore has a beta of 0.574, which suggesting that the stock is 42.566% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

electroCore has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. electroCore pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

electroCore quarterly revenues are $6.6M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. electroCore's net income of -$2.5M is higher than Xtant Medical Holdings's net income of -$5M. Notably, electroCore's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for electroCore is 4.60x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.